Literature DB >> 18079634

[Complete histological response in gastric cancer stage IV after neoadjuvant chemotherapy including S-1 combined with CDDP--report of a case].

Takashi Fujisawa1, Wataru Sano, Sachiko Ouchi, Shigemitsu Ueyama, Toshiyuki Mori, Daisuke Tsuchihashi, Osamu Uchikoga, Maki Koyanagi, Hisashi Yoshimura, Shiro Tachibana, Hirotsugu Hirano.   

Abstract

A 60-year-old man complaining of black stool, body weight loss, and anemia, was examined and diagnosed with advanced gastric cancer (M, type 3, por 2, cT3, cN3, cH0, cP0, cM0, cStage IV). A poor prognosis was predicted, yet we tried neoadjuvant chemotherapy (NAC) expecting downstaging of the tumor. Considering the efficacy and safety, we chose S-1+CDDP as the NAC regimen. S-1 (120 mg/day) was administered orally for 21 days, followed by CDDP (75 mg/body) div on day 8. Distal partial gastrectomy and lymph node dissection (D2) were performed, with Billroth I reconstruction. Histological examination of the resected stomach and lymph nodes revealed no residual cancer cells, suggesting complete histological remission (grade 3) according to the Japanese classification of gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18079634

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Long-term survival of a patient with advanced gastric cancer with paraaortic lymph node metastasis who attained pathological complete response after S-1/CDDP chemotherapy: A case report.

Authors:  Yuta Ushida; Kiyoshi Hiramatsu; Satomi Saeki; Takeshi Amemiya; Hidenari Goto; Toshiyuki Arai
Journal:  Int J Surg Case Rep       Date:  2017-08-18

2.  Long-term survival results of patients with locally advanced gastric cancer and pathological complete response after neoadjuvant chemotherapy and resection.

Authors:  Tongbo Wang; Nianchang Wang; Hong Zhou; Aiping Zhou; Jing Jin; Yingtai Chen; Dongbing Zhao
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.